Please login to the form below

Not currently logged in
Email:
Password:

Galapagos awarded milestone payment from Boehringer Ingelheim

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

The three-year collaboration announced in January 2006 involves an expansion of BioFocus DPI's SilenceSelect RNA based gene collection with an additional gene set, the development of a dedicated cellular assay in the field of autoimmune diseases, and its application in a target discovery screen for Boehringer Ingelheim's autoimmune discovery research.

Galapagos obtained upfront fees and will continue to receive R&D funding, and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for Galapagos coudl exceed EUR 2m (USD 2.7m).

Onno van de Stolpe, CEO of Galapagos, said: "This milestone speaks to BioFocus DPI's ability to deliver on longer term, higher value collaborations. We are delighted that the collaboration with Boehringer Ingelheim has progressed as planned and is on track to continue delivering value."

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics